324 related articles for article (PubMed ID: 16311254)
1. Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy.
Davies JE; Sarkar S; Rubinsztein DC
Hum Mol Genet; 2006 Jan; 15(1):23-31. PubMed ID: 16311254
[TBL] [Abstract][Full Text] [Related]
2. Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice.
Davies JE; Wang L; Garcia-Oroz L; Cook LJ; Vacher C; O'Donovan DG; Rubinsztein DC
Nat Med; 2005 Jun; 11(6):672-7. PubMed ID: 15864313
[TBL] [Abstract][Full Text] [Related]
3. Oculopharyngeal muscular dystrophy: potential therapies for an aggregate-associated disorder.
Davies JE; Berger Z; Rubinsztein DC
Int J Biochem Cell Biol; 2006; 38(9):1457-62. PubMed ID: 16530457
[TBL] [Abstract][Full Text] [Related]
4. Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear polyA-binding protein with a single-domain intracellular antibody.
Verheesen P; de Kluijver A; van Koningsbruggen S; de Brij M; de Haard HJ; van Ommen GJ; van der Maarel SM; Verrips CT
Hum Mol Genet; 2006 Jan; 15(1):105-11. PubMed ID: 16319127
[TBL] [Abstract][Full Text] [Related]
5. Cystamine suppresses polyalanine toxicity in a mouse model of oculopharyngeal muscular dystrophy.
Davies JE; Rose C; Sarkar S; Rubinsztein DC
Sci Transl Med; 2010 Jun; 2(34):34ra40. PubMed ID: 20519718
[TBL] [Abstract][Full Text] [Related]
6. Soluble expanded PABPN1 promotes cell death in oculopharyngeal muscular dystrophy.
Messaed C; Dion PA; Abu-Baker A; Rochefort D; Laganiere J; Brais B; Rouleau GA
Neurobiol Dis; 2007 Jun; 26(3):546-57. PubMed ID: 17418585
[TBL] [Abstract][Full Text] [Related]
7. Cytoplasmic targeting of mutant poly(A)-binding protein nuclear 1 suppresses protein aggregation and toxicity in oculopharyngeal muscular dystrophy.
Abu-Baker A; Laganiere S; Fan X; Laganiere J; Brais B; Rouleau GA
Traffic; 2005 Sep; 6(9):766-79. PubMed ID: 16101680
[TBL] [Abstract][Full Text] [Related]
8. Prevention of oculopharyngeal muscular dystrophy by muscular expression of Llama single-chain intrabodies in vivo.
Chartier A; Raz V; Sterrenburg E; Verrips CT; van der Maarel SM; Simonelig M
Hum Mol Genet; 2009 May; 18(10):1849-59. PubMed ID: 19258344
[TBL] [Abstract][Full Text] [Related]
9. Wild-type PABPN1 is anti-apoptotic and reduces toxicity of the oculopharyngeal muscular dystrophy mutation.
Davies JE; Sarkar S; Rubinsztein DC
Hum Mol Genet; 2008 Apr; 17(8):1097-108. PubMed ID: 18178579
[TBL] [Abstract][Full Text] [Related]
10. Animal model of oculopharyngeal muscular dystrophy.
Uyama E; Hino H; Araki K; Takeya M; Uchino M; Yamamura K
Acta Myol; 2005 Oct; 24(2):84-8. PubMed ID: 16550922
[TBL] [Abstract][Full Text] [Related]
11. Study of a Taiwanese family with oculopharyngeal muscular dystrophy.
Kuo HC; Chen CM; Lee-Chen GJ; Hu FJ; Chu CC; Liou CW; Huang CC
J Neurol Sci; 2009 Mar; 278(1-2):21-4. PubMed ID: 19101703
[TBL] [Abstract][Full Text] [Related]
12. Molecular and phenotypic characterization of a mouse model of oculopharyngeal muscular dystrophy reveals severe muscular atrophy restricted to fast glycolytic fibres.
Trollet C; Anvar SY; Venema A; Hargreaves IP; Foster K; Vignaud A; Ferry A; Negroni E; Hourde C; Baraibar MA; 't Hoen PA; Davies JE; Rubinsztein DC; Heales SJ; Mouly V; van der Maarel SM; Butler-Browne G; Raz V; Dickson G
Hum Mol Genet; 2010 Jun; 19(11):2191-207. PubMed ID: 20207626
[TBL] [Abstract][Full Text] [Related]
13. Premature proliferative arrest of cricopharyngeal myoblasts in oculo-pharyngeal muscular dystrophy: Therapeutic perspectives of autologous myoblast transplantation.
Périé S; Mamchaoui K; Mouly V; Blot S; Bouazza B; Thornell LE; St Guily JL; Butler-Browne G
Neuromuscul Disord; 2006 Nov; 16(11):770-81. PubMed ID: 17005403
[TBL] [Abstract][Full Text] [Related]
14. Oculopharyngeal muscular dystrophy (OPMD) due to a small duplication in the PABPN1 gene.
van der Sluijs BM; van Engelen BG; Hoefsloot LH
Hum Mutat; 2003 May; 21(5):553. PubMed ID: 12673802
[TBL] [Abstract][Full Text] [Related]
15. In vivo aggregation properties of the nuclear poly(A)-binding protein PABPN1.
Tavanez JP; Calado P; Braga J; Lafarga M; Carmo-Fonseca M
RNA; 2005 May; 11(5):752-62. PubMed ID: 15811916
[TBL] [Abstract][Full Text] [Related]
16. [Oculopharyngeal muscular dystrophy: study of patients from seven Spanish families with different GCG expansions in PABP2 gene].
Pou Serradell A; Lloreta Trull J; Corominas Torres JM; Hammouda EH; Urtizberea JA; Richard P; Brais B
Neurologia; 2004 Jun; 19(5):239-47. PubMed ID: 15150706
[TBL] [Abstract][Full Text] [Related]
17. Non-pathogenic protein aggregates in skeletal muscle in MLF1 transgenic mice.
Li ZF; Wu X; Jiang Y; Liu J; Wu C; Inagaki M; Izawa I; Mizisin AP; Engvall E; Shelton GD
J Neurol Sci; 2008 Jan; 264(1-2):77-86. PubMed ID: 17854834
[TBL] [Abstract][Full Text] [Related]
18. Induction of HSP70 expression and recruitment of HSC70 and HSP70 in the nucleus reduce aggregation of a polyalanine expansion mutant of PABPN1 in HeLa cells.
Wang Q; Mosser DD; Bag J
Hum Mol Genet; 2005 Dec; 14(23):3673-84. PubMed ID: 16239242
[TBL] [Abstract][Full Text] [Related]
19. Two cases of oculopharyngeal muscular dystrophy (OPMD) with the rare PABPN1 c.35G>C; p.Gly12Ala point mutation.
Robinson DO; Hilton-Jones D; Mansfield D; Hildebrand GD; Marks S; Mechan D; Ramsay J
Neuromuscul Disord; 2011 Nov; 21(11):809-11. PubMed ID: 21742497
[TBL] [Abstract][Full Text] [Related]
20. HnRNP A1 and A/B interaction with PABPN1 in oculopharyngeal muscular dystrophy.
Fan X; Messaed C; Dion P; Laganiere J; Brais B; Karpati G; Rouleau GA
Can J Neurol Sci; 2003 Aug; 30(3):244-51. PubMed ID: 12945950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
